Differences in receipt of multimodality therapy by race,insurance status, and socioeconomic disadvantage in patientswith resected pancreatic cancer
- ECU Author/Contributor (non-ECU co-authors, if there are any, appear on document)
- Scarlett Hao (Creator)
- William Irish (Creator)
- Anastasios Mitsakos (Creator)
- Alexander A. Parikh (Creator)
- Snyder Rebecca A. (Creator)
- Janet Elizabeth Tuttle-Newhall (Creator)
- Institution
- East Carolina University (ECU )
- Web Site: http://www.ecu.edu/lib/
Abstract: Background and Methods:Racial and socioeconomic disparities in receipt ofadjuvant chemotherapy affect patients with pancreatic cancer. However, differencesin receipt of neoadjuvant chemotherapy among patients undergoing resection arenot well-understood. A retrospective cross-sectional cohort of patients withresected AJCC Stage I/II pancreatic ductal adenocarcinoma was identified fromthe National Cancer Database (2014–2017). Outcomes included receipt ofneoadjuvant versus adjuvant chemotherapy, or receipt of either, defined asmultimodality therapy and were assessed by univariate and multivariate analysis.Results:Of 19 588 patients, 5098 (26%) received neoadjuvant chemotherapy, 9624(49.1%) received adjuvant chemotherapy only, and 4757 (24.3%) received nochemotherapy. On multivariable analysis, Black patients had lower odds ofneoadjuvant chemotherapy compared to White patients (OR: 0.80, 95% CI:0.67–0.97) but no differences in receipt of multimodality therapy (OR: 0.89, 95%CI: 0.77–1.03). Patients with Medicaid or no insurance, low educational attainment,or low median income had significantly lower odds of receiving neoadjuvantchemotherapy or multimodality therapy.Conclusions:Racial and socioeconomic disparities persist in receipt of neoadjuvantand multimodality therapy in patients with resected pancreatic adenocarcinoma.Discussion:Policy and interventional implementations are needed to bridge thecontinued socioeconomic and racial disparity gap in pancreatic cancer care.
Additional Information
- Publication
- Other
- Language: English
- Date: 2023
- Subjects
- healthcare disparity;multimodal treatment;neoadjuvant chemotherapy,;pancreas cancer;socioeconomic factors
| Title | Location & Link | Type of Relationship |
| Differences in receipt of multimodality therapy by race,insurance status, and socioeconomic disadvantage in patientswith resected pancreatic cancer | http://hdl.handle.net/10342/10979 | The described resource references, cites, or otherwise points to the related resource. |